Skip to content
Medical Health Aged Care

EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia

EnGeneIC 3 mins read

SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has today announced strategic partnerships with Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI). The partnerships will bring significant new funding to allow EnGeneIC to immediately progress its clinical trial programmes in Australia and the USA. Further, the agreements aim to accelerate the clinical development, manufacture and commercialisation of EnGeneIC’s proprietary technology, EnGeneIC Dream Vector (EDVTM) for cancer treatment across Asia.

The commercial deal will provide exclusive rights to SAM for sales of EDV therapeutics in Asia and net profits will be shared between the two companies with EnGeneIC receiving a majority. In addition, EnGeneIC and SAM will collaborate on the development of EDV-based theranostics. Theranostics combine therapeutic and diagnostic capabilities to improve cancer treatment outcomes. By integrating imaging and treatment into a single platform, EDV-based theranostics have the potential to provide precise, personalised care, enabling early detection and targeted therapy.

A signatory to the partnership is the Singapore based diversified property, technology and hotel entity Crescendas Group (Singapore Medical Incorporation Pte Ltd) which has committed to providing funds for the capital expenditure requirements needed to complete the next phase of clinical tests to secure Food and Drug Administration (FDA) approval in the US. Crescendas operates in Singapore, Malaysia, China and the Maldives and is owned by the prominent Singaporean businessman Mr. Lawrence Leow who is also a former nominated member of the Singapore parliament.

“Partnering with SAM and SMI marks a significant milestone for EnGeneIC, as we expand our footprint into our Asian neighbours”, said Dr. Jennifer MacDiarmid, Joint CEO of EnGeneIC. “Our EDV technology is poised to transform cancer treatment and together with our partners’ expertise and resources which will facilitate cGMP-manufacturing capability and clinical trials, we are well-positioned to bring EDVs to a much broader patient population.”

Dr. Shih Kien Djeng, Chairman and CEO of SAM said, “We are excited to collaborate with EnGeneIC to bring their cutting edge EDV-based therapeutics to Singapore and Asia. The EnGeneIC partnership aligns with our mission to advance medical innovation and improve patient outcomes. By combining our not inconsiderable strengths, we aim to deliver revolutionary cancer treatments that offer new hope to patients throughout the region.

About EnGeneIC
EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV® (EnGeneIC Dream Vector) nanocell technology for oncology and infectious disease applications. The EDVTM nanocell is the foundation of a first-in-class antibody nanocell drug conjugate platform for delivering a range of therapeutic payloads - drugs, siRNAs, miRNAs, adjuvants – via antibody-targeting a cancer cell’s surface, with minimal toxicity. For cancer applications, the EDV technology enables delivery of the most potent chemotherapeutic agents, effectively overcoming drug-resistance and killing tumor cells, while simultaneously stimulating the patient’s immune system, allowing a potent ant-tumour response. EnGeneIC is now entering Phase IIa clinical trials in Australia and USA in patients with intractable, low survival cancers, including patients with metastatic pancreatic cancer.

About Singapore Institute of Advanced Medicine Holdings
Singapore Institute of Advanced Medicine Holdings Ltd (“SAM”) is healthcare service provider in Singapore that used advanced technology for early and accurate diagnosis and the treatment of a variety of diseases and health conditions including cancer, neurodegenerative and cardiovascular diseases. SAM’s services include Nuclear Medicine and Theranostics, Proton Therapy and Radiation Therapy. SAM has strategic collaborations with public and private institutions for research
and clinical work.

EnGeneIC contact:
Dr. Jennifer MacDiarmid
Joint-CEO & Director
Email: jmacdiarmid@engeneic.com

EnGeneIC Pty Ltd,
Level 4, B53, 11 Julius Ave,
North Ryde, Sydney, NSW 2113
Australia.
Website: www.engeneic.com


Primary Logo

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.